SEARCH

SEARCH BY CITATION

References

  • 1
    Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 102840.
  • 2
    Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis, Chapter 5. In: Boyer TD, Manns MP, Sanyal AJ eds. Zakim & Boyer's Hepatology: A Textbook of Liver Disease. 6th edn. New York: Elseveir, 2012; 6485.
  • 3
    Friedman SL. Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7: 42536.
  • 4
    Mehal WZ, Iridale J, Friedman SL. Scraping fibrosis: expressway to the core of fibrosis. Nat Med 2011; 17: 5523.
  • 5
    Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology 2011; 141: 157285.
  • 6
    Malham M. Peter Jørgensen S, Lauridsen AL, Ott P, Glerup H, Dahlerup JF. The effect of a single oral megadose of vitamin D provided as either ergocalciferol (D2) or cholecalciferol (D3) in alcoholic liver cirrhosis. Eur J Gastroenterol Hepatol 2012; 24: 1728.
  • 7
    Lim LY, Chalasani N. Vitamin D deficiency in patients with chronic liver disease. Curr Gastroenterol Rep 2012; 14: 6773.
  • 8
    Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 26248.
  • 9
    Rode A, Fourlanos S, Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol 2010; 34: 61820.
  • 10
    Barchetta I, Carrotti S, Labbadia G, et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 2012; 56: 21807.
  • 11
    Charlton M, Krishnan A, Viker K, et al. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol 2011; 301: G82534.
  • 12
    Fallowfield JA. Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2011; 300: G70915.
  • 13
    Rosen CJ, Adams JS, Bikle DM, Demay MB, Manson JE, Murad MH, Kovacs CS. The nonskeletal effects of vitamin D: an endocrine society scientific statement. Endocr Rev 2012; 33: 45692.
  • 14
    Crawford BA, Labio ED, Strasser SI, McCaughan GW. Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 68999.
  • 15
    Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh J-C, Remus LS, Selznick SH, Whitfield GK. The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J Endocrinol 1997; 154: 55773.
  • 16
    Corey KE, Zheng H, Mendez-Navarro J, Delgado-Borrego A, Dienstag JL, Chung RT, HALT-C Trial Group. Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS ONE 2012; 7: e27144.
  • 17
    Potter JJ, Liu X, Koteish A, Mezey E. 1,25-dihydroxyvitamin D3 and its nuclear receptor represses human α1(I) collagen expression and type I collagen formation. Liver Int 2013; 33: 67786.
  • 18
    Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, Reif S. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut 2011; 60: 172837.
  • 19
    Nimer A, Mouch A. Vitamin D improves viral response in hepatitis C genotype 2–3 naïve patients. World J Gastroenterol 2012; 18: 8005.
  • 20
    Slominski A, Janjetovic Z, Tuckey RC, Nguyen MN, Bhattacharya KG, Wang J, Li W, Jiao Y, Gu W, Brown M, Postlethwaite AE. 20S-Hydroxyvitamin D3, noncalcemic product of CYP11A1 action on vitamin D3, exhibits potent antifibrogenic activity in vivo. J Clin Endocrinol Metab 2013; 98: E298303.